<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940617-1-00108</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4702 -->  <!-- PJG ITAG l=11 g=1 f=1 --> (I)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Sampling schedule. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) For patient preoperative skin  <!-- PJG 0012 frnewline --> preparation antiseptic drug products labeled according to  <!-- PJG 0012 frnewline --> &sect;333.460(b)(1), the treatment is randomly assigned to one  <!-- PJG 0012 frnewline --> contralateral groin site and one contralateral abdominal site on  <!-- PJG 0012 frnewline --> each of the subjects. The assignment is to be balanced such that  <!-- PJG 0012 frnewline --> an equal number of right and left sites in each anatomical area  <!-- PJG 0012 frnewline --> receive treatment. The untreated contralateral sites serve as  <!-- PJG 0012 frnewline --> control sites to establish baseline populations. Collect a  <!-- PJG 0012 frnewline --> baseline bacterial sample from one untreated groin site and from  <!-- PJG 0012 frnewline --> one abdominal site on each subject using the scrub cup technique  <!-- PJG 0012 frnewline --> just prior to application of the preoperative skin treatment to the corresponding contralateral site. Ten minutes after  <!-- PJG 0012 frnewline --> treatment, sample one treated groin site and one treated  <!-- PJG 0012 frnewline --> abdominal site on one-third of the subjects using the same  <!-- PJG 0012 frnewline --> sampling technique. Thirty minutes posttreatment, sample another  <!-- PJG 0012 frnewline --> one-third of the subjects as before, and 6 hours posttreatment,  <!-- PJG 0012 frnewline --> sample the remaining one-third of the subjects.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Between the time of treatment allocation and the 6-hour sampling interval, the subjects <!-- PJG 0034 unknown -->  movements should be  <!-- PJG 0012 frnewline --> restricted. Subjects treated in the groin area should avoid  <!-- PJG 0012 frnewline --> activities or positions that would cause untreated skin sites to  <!-- PJG 0012 frnewline --> contact treated sites or clothing. Positions that might be  <!-- PJG 0012 frnewline --> appropriate are lying on the back or sitting with the legs  <!-- PJG 0012 frnewline --> extended without flexing from the trunk. To allow subjects some  <!-- PJG 0012 frnewline --> degree of mobility between the time of treatment and the 4-hour  <!-- PJG 0012 frnewline --> posttreatment sampling, the treated skin areas should be loosely  <!-- PJG 0012 frnewline --> draped with a sterile nonocclusive dressing. This material is to  <!-- PJG 0012 frnewline --> be applied in such a manner as to protect the treated skin sites  <!-- PJG 0012 frnewline --> from contact with untreated skin.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 3 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) For patient preoperative skin preparation antiseptic  <!-- PJG 0012 frnewline --> drug products labeled according to &sect;333.460(b)(2), the treatment  <!-- PJG 0012 frnewline --> is randomly assigned to contralateral dry skin sites on each of  <!-- PJG 0012 frnewline --> the subjects. The assignment is to be balanced such that an  <!-- PJG 0012 frnewline --> equal number of right and left sites in each anatomical area  <!-- PJG 0012 frnewline --> receive treatment. The untreated contralateral site serves as a  <!-- PJG 0012 frnewline --> control site to establish baseline populations. Collect a baseline bacterial sample from an untreated site on each subject  <!-- PJG 0012 frnewline --> using the scrub cup technique just prior to application of the  <!-- PJG 0012 frnewline --> preoperative skin preparation to the corresponding contralateral  <!-- PJG 0012 frnewline --> site. Thirty seconds after application, sample the treated site  <!-- PJG 0012 frnewline --> using the same sampling technique.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (J)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Microbiological methods. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Samples for bacterial  <!-- PJG 0012 frnewline --> enumeration are obtained by the detergent scrub cup technique.  <!-- PJG 0012 frnewline --> Hold a sterile scrubbing cup firmly to the skin. Aseptically  <!-- PJG 0012 frnewline --> pipet 2.5 milliliters of sterile sampling solution into the  <!-- PJG 0012 frnewline --> scrubbing cup and rub the skin with a sterile rubber policeman  <!-- PJG 0012 frnewline --> for 1 minute using moderate pressure. Aspirate the wash fluid  <!-- PJG 0012 frnewline --> and place in a sterile test tube. Place a second 2.5-milliliter  <!-- PJG 0012 frnewline --> aliquot of sampling solution in the scrub cup and rub the skin  <!-- PJG 0012 frnewline --> again for 1 minute with the rubber policeman. Pool the two  <!-- PJG 0012 frnewline --> washes and enumerate the bacteria.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (K)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Enumeration of bacteria in sampling solution.  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> )  <!-- PJG 0012 frnewline --> Enumerate the bacteria in the sampling solution by a standard  <!-- PJG 0012 frnewline --> plate count procedure such as that described in ``Standard Methods  <!-- PJG 0012 frnewline --> for the Evaluation of Dairy Products'' (available from American  <!-- PJG 0012 frnewline --> Public Health Association, Inc., 1015 15th St. NW., Washington,  <!-- PJG 0012 frnewline --> DC 20005) but using soybean-casein digest agar and a suitable  <!-- PJG 0012 frnewline --> inactivator for the antimicrobial where necessary. The  <!-- PJG 0012 frnewline --> suitability of the inactivator is to be demonstrated using a  <!-- PJG 0012 frnewline --> procedure such as described in E 1054, ``Test Methods for  <!-- PJG 0012 frnewline --> Evaluating Inactivators of Antimicrobial Agents Used in Disinfectant, Sanitizer, and Antiseptic Products,'' in ``Annual  <!-- PJG 0012 frnewline --> Book of ASTM Standards,'' vol. 11.04, which is incorporated by  <!-- PJG 0012 frnewline --> reference in accordance with 5 U.S.C. 552(a) and 1 CFR part 51.  <!-- PJG 0012 frnewline --> Copies are available from The American Society for Testing and  <!-- PJG 0012 frnewline --> Materials, 1916 Race St., Philadelphia, PA 19103&hyph;1187, or may be  <!-- PJG 0012 frnewline --> examined at the Center for Drug Evaluation and Research, 7520  <!-- PJG 0012 frnewline --> Standish Pl., suite 201, Rockville, MD, or at the Office of the  <!-- PJG 0012 frnewline --> Federal Register, 800 North Capitol St. NW., suite 700,  <!-- PJG 0012 frnewline --> Washington, DC. Prepare sample dilutions in dilution fluid.  <!-- PJG 0012 frnewline --> Plate in duplicate. Incubate plated sample at 30  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=6 f=1 --> # <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  2  <!-- PJG 0040 degreeslatlong --> &cir;C for 48  <!-- PJG 0012 frnewline --> hours before reading.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 2 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) Determine changes from baseline counts obtained with  <!-- PJG 0012 frnewline --> the test material at each sampling interval for each anatomical  <!-- PJG 0012 frnewline --> site. For a more realistic appraisal of the activity of  <!-- PJG 0012 frnewline --> products, all raw data should be converted to common (base 10)  <!-- PJG 0012 frnewline --> logarithms. Reduction should be calculated from the average of  <!-- PJG 0012 frnewline --> the logarithms. This will also facilitate statistical analysis  <!-- PJG 0012 frnewline --> of data.  <!-- PJG 0012 frnewline -->   <!-- PJG 0012 frnewline --> (L)  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> Comparison of test material with control material. <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->   <!-- PJG 0012 frnewline --> ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> 1 <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> ) In order to validate the testing procedure, equipment, and  <!-- PJG 0012 frnewline --> facilities, it is required that the test material be compared  <!-- PJG 0012 frnewline --> with an active control material. The number of test subjects  <!-- PJG 0012 frnewline --> will depend upon the number of control posttreatment sampling  <!-- PJG 0012 frnewline --> intervals chosen and the level of statistical significance  <!-- PJG 0012 frnewline --> desired for the test results. The identity of the formulations  <!-- PJG 0012 frnewline --> used by panelists should be blinded from those individuals  <!-- PJG 0012 frnewline --> counting plates and analyzing data.  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            